Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
DXCM Stock Chart & Stats
$61.18
$0.53(0.67%)
At close: 4:00 PM EST
$61.18
$0.53(0.67%)
Day’s Range― - ―
52-Week Range$56.45 - $93.25
Previous CloseN/A
Volume488.69K
Average Volume (3M)6.10M
Market Cap
$23.86B
Enterprise Value$26.67B
Total Cash (Recent Filing)$3.32B
Total Debt (Recent Filing)$2.52B
Price to Earnings (P/E)34.1
Beta1.20
Next Earnings
Feb 05, 2026EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.61
Shares Outstanding390,016,270
10 Day Avg. Volume8,222,194
30 Day Avg. Volume6,098,487
Financial Highlights & Ratios
PEG Ratio39.32
Price to Book (P/B)14.97
Price to Sales (P/S)7.80
P/FCF Ratio49.89
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue5.91
Enterprise Value/Gross Profit10.01
Enterprise Value/Ebitda21.90
Forecast
1Y Price Target
$88.58Price Target Upside44.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)2.07
Revenue Forecast (FY)$4.64B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow And Share RepurchaseDXCM has the best FCF as a % of net income in Medtech and is tied with ISRG at the top as a % of revenue, giving DXCM flexibility to repurchase shares at a disclosed valuation.
Management Confidence And Shareholder ValueManagement has plans to repurchase shares, indicating confidence in the company’s future, and margins have meaningful expansion opportunities as the company moves past gross margin headwinds.
Revenue Growth And Market PerformanceQ3 US revenue was slightly ahead of CGe and above consensus estimates, with Stelo revenue exceeding $100M in the first year of launch.
Bears Say
Financial Guidance And MarginsThe guide was disappointing with 2025 revenue lifted to reflect Q3 results but GM and adjusted EBITDA guidance lowered as costs related to quality issues continue to impact the P&L.
Market Sentiment And Stock ReactionShares are trading down more than 10% after hours due to lower than hoped for U.S. sales growth and 2026 commentary below the Street.
Product Reliability And Reputational RisksWidely reported G7 reliability issues added to a series of overhangs that have weighed on DXCM over the past couple years, with risk that the reliability narrative begins to weigh on new starts.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $56.45 and its highest was $93.25 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $23.86B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Feb 05, 2026 which is in 91 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Oct 30, 2025. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.576 by $0.034.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.65.
How many shares outstanding does Dexcom have?
Dexcom has 390,016,270 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.61 in its last earnings report, beating expectations of $0.576. Following the earnings report the stock price went down -14.633%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
Dexcom Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.58 (44.79% Upside)
$88.58 (44.79% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 139.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.22%
12-Months-Change
Fundamentals
Return on Equity
30.63%
Trailing 12-Months
Asset Growth
18.04%
Trailing 12-Months
Company Description
Dexcom
Dexcom, Inc. is a global leader in continuous glucose monitoring (CGM) technology, primarily serving individuals with diabetes. Founded in 1999 and headquartered in San Diego, California, Dexcom develops and manufactures state-of-the-art CGM systems that provide real-time glucose readings, allowing users to manage their diabetes more effectively. The company's core products include the Dexcom G6 and G7 CGM systems, which are designed to provide accurate, timely glucose data to patients and healthcare providers, facilitating better decision-making regarding insulin dosing and lifestyle management.
DXCM Company Deck
DXCM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
DexCom's earnings call highlighted robust revenue growth and strategic product expansions, particularly in type 2 diabetes CGM coverage, and noted the introduction of innovative products like DexCom Smart Basal. However, challenges in gross margin management and quality issues with the G7 sensor deployment were noted. The sentiment is buoyed by positive financial performance and strategic advancements, despite some operational challenges.View all DXCM earnings summariesDXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
DXCM Stock 12 Month Forecast
Average Price Target
$88.58
▲(44.79% Upside)
Technical Analysis
Ownership Overview
0.47% Insiders
29.72% Mutual Funds
0.57% Other Institutional Investors
39.83% Public Companies and Individual Investors